Bionano Genomics (BNGO) Cash from Financing Activities (2017 - 2026)

Bionano Genomics has reported Cash from Financing Activities for 10 years, with the latest figure at $657000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 93.97% year-over-year to $657000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.8 million (down 26.66% YoY) and the FY2025 annual result came in at $24.0 million, up 275.66% from the prior year.
• Cash from Financing Activities eased to $657000.0 in Q1 2026 per BNGO's latest filing, from $1.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $68.5 million in Q4 2023 and troughed at -$21.6 million in Q1 2024.
• A 5-year average of $8.7 million and a median of $3.9 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities soared 212214.29% in 2023, then plunged 245.46% in 2024.
• Over 5 years, Cash from Financing Activities stood at $146000.0 in 2022, then soared by 46806.85% to $68.5 million in 2023, then slumped by 94.32% to $3.9 million in 2024, then sank by 58.79% to $1.6 million in 2025, then slumped by 59.01% to $657000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $657000.0, $1.6 million, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.